Cannabinoids are found in the cannabis plant, they can be produced in biosynthesis way. While biosynthesis has not yet proven itself as a scalable technology, it has the potential to radically alter the way cannabinoids are manufactured in the near future.These compounds are the exact same as what cannabis expresses.

In 2021, the global Biosynthesis of Cannabinoids market size will be US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027.
This report focuses on the global Biosynthesis of Cannabinoids status, future forecast, growth opportunity, key market, and key players. The study objectives are to present the Biosynthesis of Cannabinoids development in North America, Europe, Japan, China, Southeast Asia, India, etc.

Global Biosynthesis of Cannabinoids Scope and Market Size
Biosynthesis of Cannabinoids market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Biosynthesis of Cannabinoids market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
THC
CBD
Others

Segment by Application
Food Industry
Medical Industry
Others

By Region
North America
Europe
Japan
China
Southeast Asia
India

By Company
Anandia Laboratories
Gingko Bioworks
Hyasynth Bio
InMed Pharmaceuticals
Librede
Renew Biopharma
Cronos Group
Organigram
Teewinot Life Sciences
ICC International Cannabis Corp.
Biotii Technologies Corp.
Bristol-Myers Squibb
Biogen Inc.
GW Pharmaceuticals